BioTime (BTX) : Traders are bullish on BioTime (BTX) as it has outperformed the S&P 500 by a wide margin of 10.98% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4% in the last 1 week, and is up 14.71% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.88% and the 50-Day Moving Average is 13.61%. BioTime, Inc. is up 6.85% in the last 3-month period. Year-to-Date the stock performance stands at -23.9%.
BioTime (NYSEMKT:BTX): On Fridays trading session , Opening price of the stock was $3.12 with an intraday high of $3.18. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.03. However, the stock managed to close at $3.12, a loss of 0.95% for the day. On the previous day, the stock had closed at $3.15. The total traded volume of the day was 876,222 shares.
BioTime, Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines, including tissue banking, cellular therapy, gene therapy and tissue engineering. The Company is engaged to develop cell-based therapeutic products for diseases, such as neurological disorders, cancer, age related macular degeneration, orthopedic disorders, and age-related cardiovascular disease.